371 related articles for article (PubMed ID: 16352699)
1. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
[TBL] [Abstract][Full Text] [Related]
2. Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors.
Bergman J; Yasar S; Winger G
Psychopharmacology (Berl); 2001 Dec; 159(1):21-30. PubMed ID: 11797065
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats.
Yasar S; Schindler CW; Thorndike EB; Szelenyi I; Goldberg SR
J Pharmacol Exp Ther; 1993 Apr; 265(1):1-6. PubMed ID: 8473997
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats.
Yasar S; Schindler CW; Thorndike EB; Goldberg SR
Eur J Pharmacol; 1994 Jul; 259(3):243-50. PubMed ID: 7982450
[TBL] [Abstract][Full Text] [Related]
5. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
Engberg G; Elebring T; Nissbrandt H
J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
[TBL] [Abstract][Full Text] [Related]
6. Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys.
Yasar S; Gaal J; Justinova Z; Bergman J
Psychopharmacology (Berl); 2005 Oct; 182(1):95-103. PubMed ID: 15990999
[TBL] [Abstract][Full Text] [Related]
7. A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.
Yasar S; Gaál J; Panlilio LV; Justinova Z; Molnár SV; Redhi GH; Schindler CW
Psychopharmacology (Berl); 2006 Jan; 183(4):413-21. PubMed ID: 16292593
[TBL] [Abstract][Full Text] [Related]
8. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
Youdim MB; Tipton KF
Parkinsonism Relat Disord; 2002 Mar; 8(4):247-53. PubMed ID: 12039419
[TBL] [Abstract][Full Text] [Related]
9. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
Yoshida T; Yamada Y; Yamamoto T; Kuroiwa Y
Xenobiotica; 1986 Feb; 16(2):129-36. PubMed ID: 3083608
[TBL] [Abstract][Full Text] [Related]
11. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic aspects of deprenyl effects.
Magyar K; Tóthfalusi L
Pol J Pharmacol Pharm; 1984; 36(4):373-84. PubMed ID: 6441926
[TBL] [Abstract][Full Text] [Related]
13. L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.
He S; Grasing K
Pharmacol Biochem Behav; 2006 Dec; 85(4):675-88. PubMed ID: 17157368
[TBL] [Abstract][Full Text] [Related]
14. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
Karoum F
Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
[TBL] [Abstract][Full Text] [Related]
15. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research.
Yasar S; Goldberg JP; Goldberg SR
J Neural Transm Suppl; 1996; 48():61-73. PubMed ID: 8988462
[TBL] [Abstract][Full Text] [Related]
16. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
17. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
Haberle D; Szökõ E; Magyar K
Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
[TBL] [Abstract][Full Text] [Related]
18. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Magyar K; Szende B
Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
[TBL] [Abstract][Full Text] [Related]
19. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
Severina IS
Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
[TBL] [Abstract][Full Text] [Related]
20. The effect of repeated administration of (-) deprenyl on the phenylethylamine-induced stereotypy in rats.
Timár J; Knoll B
Arch Int Pharmacodyn Ther; 1986 Jan; 279(1):50-60. PubMed ID: 3083795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
